Zhongsheng Pharma's Unit Gets Patent From Japan for the Ketoamide-Inducing Method for Leritrelvir Tablets
Guangdong Zhongsheng Pharmaceutical's (SHE:002317) unit, Guangdong Zhong Sheng Ruichuang Biotechnology, received a patent certificate from Japan for a ketoamide inducing method, according to a Tuesday disclosure on the Shenzhen bourse.The 20-year patent is for the crystal form of a ketoamide derivative and preparation method, which is for the company's oral anti-COVID-19 drug Leritrelvir Tablets, with the brand name Leruiling.Shares of the pharmaceutical company closed 3% higher.